The Biden administration has released a plan for federal officials to use "march-in rights," a policy through which the government could seize the patents of drugs made using federal funds, if drug costs climb too high. Under the framework released Thursday, officials can consider the price of a drug when deciding whether to seize a patent.
Bloomberg reports that administration officials have kept mum about which drug patents they're looking at, but the White House did say in a statement that more competition can push prices down.
